Axatilimab not checked
Incyte · Syndax Pharmaceuticals · INCA034176 · SNDX-6352
FollowEvery change as it happens, and a Monday email
Trials
7 active
12 in total · 6 in the EU
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
- How it’s given
- “Axatilimab is a high-affinity antibody targeting the colony stimulating factor 1 receptor (CSF-1R). CSF-1R signaling has been demonstrated in nonclinical studies to be the key regulatory pathway involved in the expansion and infiltration of donor-derived macrophages that mediate the disease processes involved in cGVHD.”In the company’s words, NCT04710576 on ClinicalTrials.gov
- Tested for
- Chronic Graft-versus-host-disease (7 trials)
- Main trialPhase 3
- “This study will be conducted to determine the clinical efficacy of axatilimab in Japanese participants with chronic graft-versus-host disease (cGVHD).”In the company’s words, NCT06263478 on ClinicalTrials.gov
- Other names
- INCA034176 · Niktimvo · SNDX-6352
Other drugs for Chronic Graft-versus-host-disease
- IbrutinibJohnson & Johnson (Janssen) · Phase 3
- DFL24498Dompé Farmaceutici S.p.A · Phase 3
- RovadicitinibChia Tai Tianqing Pharmaceutical Group Co., Ltd. · Phase 2
- Autologous HB-adMSCsHope Biosciences LLC · Phase 2
- TVAX-008Grand Theravac Life Sciences (Nanjing) Co., Ltd. · Phase 1/2
- AHB-171Ausper Biopharma Co., Ltd. · Phase 2
Coming up4
- 6 Jan 2027Phase 1/2 trial completes · ClinicalTrials.gov
- 28 Sep 2027Phase 3 trial completes · ClinicalTrials.gov
- 31 May 2028Phase 3 trial completes · ClinicalTrials.gov
- 31 Jan 2029Phase 2 trial completes · ClinicalTrials.gov
Changes2
Last 90 days- 16 NovStatus changed: Active, not recruiting to Completed · ClinicalTrials.gov NCT06132256
- 16 NovCompletion date moved: 2026-09 to 2026-08-27 · ClinicalTrials.gov NCT06132256
Trials12
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 6 Aug 2025 | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Axatilimab Monotherapy in Japanese Participants With Recurrent or Refractory Active Chronic Graft-Versus-Host Disease | |
| Phase 3Recruiting | 28 Sep 2027 | A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | |
| Phase 3Active, not recruiting | 31 May 2028 | A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy | |
| Phase 2Recruiting | 7 Apr 2023 | A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD) | |
| Phase 2Active, not recruiting | 1 Oct 2026 | A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease | |
| Phase 2Recruiting | 31 Jan 2029 | A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256) | |
| Phase 1/2Active, not recruiting | 6 Jan 2027 | A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD | |
| Phase 2Terminated | 13 Jul 2020 | A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19 | |
| Phase 2Completed | 27 Aug 2026 | MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF) | |
| Phase 1/2Completed | 12 Aug 2022 | A Phase 1/2 Study to Evaluate Axatilimab in Participants With Active cGVHD | |
| Phase 1Completed | 20 Nov 2020 | A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors | |
| Phase 1Completed | 6 Jun 2025 | A Study to Evaluate a Single-Dose Subcutaneous Axatilimab Compared With Intravenous Axatilimab in Healthy Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026